Toll-like receptor 4–Myeloid differentiation factor 2 complex (TLR4–MD-2)

The Toll-like receptor 4–Myeloid differentiation factor 2 (TLR4–MD-2) complex is a pivotal component of the innate immune system, serving as the primary sensor for lipopolysaccharide (LPS) from Gram-negative bacteria [1, 2]. TLR4 is a type I transmembrane protein that lacks a direct LPS-binding site and thus relies on the extracellular accessory protein MD-2 (also known as Lymphocyte antigen 96) to capture the lipid A moiety of endotoxins [1, 4]. Upon binding LPS, the TLR4–MD-2 complex forms a symmetrical dimer, which triggers intracellular signaling through the MyD88 and TRIF pathways [2, 3]. This activation leads to the production of pro-inflammatory cytokines, such as TNF-α and IL-6, which are essential for the host's defense against infection [1, 4]. However, excessive or chronic activation of this complex is implicated in the pathogenesis of sepsis, autoimmune disorders, and neuroinflammation [4, 5]. Consequently, the TLR4–MD-2 complex is a major therapeutic target, with drug development focusing on antagonists like Eritoran to treat inflammatory diseases and agonists like monophosphoryl lipid A (MPLA) used as vaccine adjuvants [2, 3]. Challenges in targeting this complex include significant species-specific differences in ligand recognition and the risk of inducing immunosuppression [4].

Other names

TLR4-MD2 complexTLR4-LY96 complexCD284-LY96 complexLymphocyte antigen 96-Toll-like receptor 4 complex

The TLR4–MD-2 complex recognizes lipopolysaccharide (LPS) through the binding of the lipid A moiety into the hydrophobic pocket of MD-2 [1, 2]. This binding event induces the dimerization of two TLR4–MD-2 heterodimers, which facilitates the juxtaposition of their intracellular Toll/interleukin-1 receptor (TIR) domains [2, 3]. The dimerized TIR domains recruit adapter proteins, specifically MyD88 and TRIF, which initiate downstream signaling pathways [3, 4]. These pathways culminate in the activation of transcription factors such as NF-κB and IRF3, driving the production of pro-inflammatory cytokines and interferons [1, 4].